Home > Insider Trading > Filing (0000899243-16-021788)

Filing Details

Accession Number:: 0000899243-16-021788
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-06-06 16:18:58
Reporting Period:: 2016-06-02

Filing Date:: 2016-06-06
Accepted Time:: 2016-06-06 16:18:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501989	Cytomx Therapeutics Inc.	CTMX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1207114	M Timothy Shannon	285 Riverside Avenue Suite 250 Westport CT 06880		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-06-02	41,193	$10.79	4,422,734	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2016-06-03	18,428	$10.83	4,404,306	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	134	Direct

Footnotes

These shares of Common Stock ("Shares") are held directly by Canaan IX L.P. The Reporting Person is a non-managing member of Canaan Partners IX LLC, the general partner of Canaan IX L.P. The Reporting Person does not have voting, investment or dispositive power over any of the Shares directly held by Canaan IX L.P. and disclaims beneficial ownership of the Shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the Shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $10.55 - $11.09, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in footnote (2) of this Form 4.
The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $10.585 - $11.08, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the range set forth in footnote (3) of this Form 4.